title: Induction of tolerance to hepatitis B virus: can we 'eat the disease' and live with the virus?
abstract: Hepatitis B virus (HBV) is a major health problem, with over 300 million HBsAg carriers worldwide. The HBV itself is non-cytopathic, and it is widely accepted that the mechanism of hepatocellular injury is the host anti-viral immune response. Current treatments, including the newly developed therapeutic modalities, are either based on antiviral drugs or focus on attempts to augment the anti-viral immune response. The results of these approaches have been largely disappointing. There is evidence, however, that subjects with a natural tolerance to HBV or a down-regulated immune response develop little or no liver injury, despite chronic viremia. Lately, it has been shown that it is possible to induce tolerance toward viruses by oral administration of major viral structural proteins. Here, we discuss the pathogenesis of HBV-mediated liver disease and approaches to down-regulate the immune response directed against liver cells by orally inducing tolerance toward the virus. We hypothesize that this acquired tolerance should turn chronic active hepatitis patients with deteriorating disease into 'healthy' virus carriers. The proposed new treatment strategy would redirect the focus from augmenting anti-viral immune response to inducing host tolerance towards the virus.
authors.affiliation: Marion Bessin Liver Research Center, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Ilan
authors.forename: J R
authors.initials: JR
authors.lastname: Chowdhury
mesh_terms: D000818:Animals; D002353:Carrier State; D015536:Down-Regulation; D006509:Hepatitis B / Q000453:epidemiology; D006511:Hepatitis B Antigens / Q000276:immunology; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy; D018448:Models, Immunological
chemical_list: D006511:Hepatitis B Antigens